Mode
Text Size
Log in / Sign up
N/A N=105

Evaluation of a Powered Surgical Stapler in Video-Assisted Thoracoscopic Lung Resection Procedures in Korea

Non-small Cell Lung Cancer (NSCLC)

Enrolled (actual)
105
Serious AEs
11.4%
Results posted
Dec 2015
Primary outcome: Primary: Occurrence of Prolonged Air Leaks — 0.0; 5.8; 37.5 percentage of participants

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
Endocutter (Device)
Age
Adult, Older Adult · 19+ yrs
Sex
All
Sponsor
Ethicon Endo-Surgery
Primary completion
Jan 2015

Outcome Measures

OutcomeResultp-value
PRIMARY
Occurrence of Prolonged Air Leaks
0.0; 5.8; 37.5
SECONDARY
Occurrence of Postoperative Air Leaks
30.8; 42.0; 75.0
SECONDARY
Length of Stay (LOS)
7.2; 9.3; 9.4
SECONDARY
Volume of Estimated Intra-operative Blood Loss
30.4; 146.1; 91.3
SECONDARY
Time to Chest Tube Removal
3.4; 5.2; 6.3

Summary

Collection of real world outcomes of Video-Assisted Thoracoscopic Surgery (VATS) for lung cancer (lobectomy, wedge resection) using ECHELON FLEX™ Powered ENDOPATH® Staplers 45 mm and/or 60 mm (study devices) in a Korean population.

Eligibility Criteria

Inclusion Criteria

  • Suspected or confirmed of NSCLC (up to and including Stage II), or individuals undergoing VATS diagnostic wedge resection in accordance with their institution's Standard of care (SOC);
  • Scheduled for lung resection surgery (lobectomy or wedge resection) involving only one lobe of the lung;
  • Performance status 0-1 (Eastern Cooperative Oncology Group classification);
  • ASA score ≤ 3;
  • No prior history of VATS or open lung surgery;
  • Willing to give consent and comply with study-related evaluation and treatment schedule; and
  • At least 19 years of age.

Exclusion Criteria

  • Active (subject currently receiving systemic treatment) bacterial infection or fungal infection;
  • Systemic administration (intravenous or oral) of steroids, including herbal supplements that contain steroids, (within 30 days prior to study procedure);
  • Chemotherapy or radiation therapy for lung cancer may not be performed for 30 days prior to the procedure;
  • Scheduled concurrent surgical procedure other than wedge resection or lobectomy (central venous access - e.g., port placement, mediastinoscopy with lymph node sampling, and VATS lymphadenectomy are allowed);
  • Pregnancy;
  • Physical or psychological condition which would impair study participation;
  • The patient is judged unsuitable for study participation by the Investigator for any other reason; or
  • Unable or unwilling to attend follow-up visits and examinations.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02196675). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search